150 related articles for article (PubMed ID: 12087465)
1. Expression of basic fibroblast growth factor is associated with poor outcome in non-Hodgkin's lymphoma.
Pazgal I; Zimra Y; Tzabar C; Okon E; Rabizadeh E; Shaklai M; Bairey O
Br J Cancer; 2002 Jun; 86(11):1770-5. PubMed ID: 12087465
[TBL] [Abstract][Full Text] [Related]
2. Angiogenesis and mast cells in non-Hodgkin's lymphoma: a strong correlation in angioimmunoblastic T-cell lymphoma.
Fukushima N; Satoh T; Sano M; Tokunaga O
Leuk Lymphoma; 2001 Aug; 42(4):709-20. PubMed ID: 11697501
[TBL] [Abstract][Full Text] [Related]
3. A high pretreatment serum basic fibroblast growth factor concentration is an independent predictor of poor prognosis in non-Hodgkin's lymphoma.
Salven P; Teerenhovi L; Joensuu H
Blood; 1999 Nov; 94(10):3334-9. PubMed ID: 10552942
[TBL] [Abstract][Full Text] [Related]
4. The expression of fibroblast growth factors and their receptors in Hodgkin's lymphoma.
Khnykin D; Troen G; Berner JM; Delabie J
J Pathol; 2006 Feb; 208(3):431-8. PubMed ID: 16353171
[TBL] [Abstract][Full Text] [Related]
5. Prognostic implications of the differentiation inhibitory factor nm23-H1 protein in the plasma of aggressive non-Hodgkin's lymphoma.
Niitsu N; Okabe-Kado J; Kasukabe T; Yamamoto-Yamaguchi Y; Umeda M; Honma Y
Blood; 1999 Nov; 94(10):3541-50. PubMed ID: 10552965
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical expression of basic fibroblast growth factor, vascular endothelial growth factor, and their receptors in stage IV non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Appl Immunohistochem Mol Morphol; 2002 Dec; 10(4):316-21. PubMed ID: 12607599
[TBL] [Abstract][Full Text] [Related]
7. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Giles FJ; Vose JM; Do KA; Johnson MM; Manshouri T; Bociek G; Bierman PJ; O'Brien SM; Kantarjian HM; Armitage JO; Albitar M
Leuk Res; 2004 Jun; 28(6):595-604. PubMed ID: 15120936
[TBL] [Abstract][Full Text] [Related]
8. Magnitude of stromal hemangiogenesis correlates with histologic subtype of non-Hodgkin's lymphoma.
Ruan J; Hyjek E; Kermani P; Christos PJ; Hooper AT; Coleman M; Hempstead B; Leonard JP; Chadburn A; Rafii S
Clin Cancer Res; 2006 Oct; 12(19):5622-31. PubMed ID: 17020964
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of basic fibroblast growth factor in breast carcinoma and its relationship to vascular density, oestrogen receptor, epidermal growth factor receptor and survival.
Smith K; Fox SB; Whitehouse R; Taylor M; Greenall M; Clarke J; Harris AL
Ann Oncol; 1999 Jun; 10(6):707-13. PubMed ID: 10442194
[TBL] [Abstract][Full Text] [Related]
10. High serum hepatocyte growth factor level in patients with non-Hodgkin's lymphoma.
Hsiao LT; Lin JT; Yu IT; Chiou TJ; Liu JH; Yen CC; Wang WS; Chen PM
Eur J Haematol; 2003 May; 70(5):282-9. PubMed ID: 12694163
[TBL] [Abstract][Full Text] [Related]
11. Gelatinases (MMP-2 and MMP-9), TIMP-1 expression and the extent of neovascularization in aggressive non-Hodgkin's lymphomas.
Kuittinen O; Apaja-Sarkkinen M; Turpeenniemi-Hujanen T
Eur J Haematol; 2003 Aug; 71(2):91-9. PubMed ID: 12890147
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of vascular endothelial growth factor, basic fibroblastic growth factor, and microvessel density and their relation to cell proliferation in B-cell non-Hodgkin's lymphoma.
Alshenawy HA
Ann Diagn Pathol; 2010 Oct; 14(5):321-7. PubMed ID: 20850693
[TBL] [Abstract][Full Text] [Related]
13. Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin's lymphoma.
Mazur G; Wróbel T; Dziegiel P; Jeleń M; Kuliczkowski K; Zabel M
Folia Histochem Cytobiol; 2004; 42(4):241-3. PubMed ID: 15704651
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma.
Abdulrauf SI; Edvardsen K; Ho KL; Yang XY; Rock JP; Rosenblum ML
J Neurosurg; 1998 Mar; 88(3):513-20. PubMed ID: 9488306
[TBL] [Abstract][Full Text] [Related]
15. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours.
Li VW; Folkerth RD; Watanabe H; Yu C; Rupnick M; Barnes P; Scott RM; Black PM; Sallan SE; Folkman J
Lancet; 1994 Jul; 344(8915):82-6. PubMed ID: 7516992
[TBL] [Abstract][Full Text] [Related]
16. Effects of microvascular density on primary pulmonary non-Hodgkin's lymphoma (PPL).
Yang M; Zhao S; Zhang X; Wang X; Zhang M; Wang Y; Zhang Q
Tumour Biol; 2012 Dec; 33(6):2143-50. PubMed ID: 22875783
[TBL] [Abstract][Full Text] [Related]
17. Tumor angiogenesis in pulmonary adenocarcinomas: relationship with basic fibroblast growth factor, its receptor, and survival.
Takanami I; Tanaka F; Hashizume T; Kodaira S
Neoplasma; 1997; 44(5):295-8. PubMed ID: 9473788
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of microvessel density and vascular endothelial growth factor (VEGF) expression in non-Hodgkin's lymphoma.
Hazar B; Paydas S; Zorludemir S; Sahin B; Tuncer I
Leuk Lymphoma; 2003 Dec; 44(12):2089-93. PubMed ID: 14959852
[TBL] [Abstract][Full Text] [Related]
19. Composite lymphoma. A clinicopathologic analysis of nine patients with Hodgkin's disease and B-cell non-Hodgkin's lymphoma.
Gonzalez CL; Medeiros LJ; Jaffe ES
Am J Clin Pathol; 1991 Jul; 96(1):81-9. PubMed ID: 2069139
[TBL] [Abstract][Full Text] [Related]
20. Effect of age on the characteristics and clinical behavior of non-Hodgkin's lymphoma patients. The Non-Hodgkin's Lymphoma Classification Project.
Ann Oncol; 1997 Oct; 8(10):973-8. PubMed ID: 9402170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
